

Our Ref: 499/2022  
JANUARY 2022

**Re: Your request made under the Freedom of Information Act 2000**

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- Benralizumab - 6
- Dupilumab - 17
- Omalizumab - 5
- Reslizumab - 0
- Mepolizumab - 35
- Tezepelumab - 0

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- Age 6-11 - 0
- Age 12-17 - 0
- Age 18 and above - 63

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with :

- Dupilumab - 1
- Omalizumab - 4